At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.
Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
Access earnings press release, webcast link and slides for Gilead’s second quarter 2014 results. View materials.
July 25, 2014
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma